AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37430305 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Supported Agriculture (CSA) intervention
Number of subjects: 305
Study 37430314 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-68
Number of subjects: 22
Study 37430314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 37430359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed fluid therapy (GDFT)
Number of subjects: 276
Study 37430359 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid therapy (RFT)
Number of subjects: 276
Study 37430361 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 636
Study 37430361 — intervention group
Group type: COMPARATOR
Intervention: Non-General Anesthesia (non-GA)
Number of subjects: 636
Study 37430375 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-CRRT penKid levels
Number of subjects: 0
Study 37430375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-CRRT penKid levels
Number of subjects: 0
Study 37430375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low penKid levels on day 3 of CRRT
Number of subjects: 0
Study 37430375 — intervention group
Group type: EXPERIMENTAL
Intervention: High daily urinary output (> 436 ml/d)
Number of subjects: 0
Study 37430546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 5 (FC5)
Number of subjects: 70
Study 37430546 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular rhythm notification (IRN) feature of FC5
Number of subjects: 70
Study 37431294 — intervention group
Group type: EXPERIMENTAL
Intervention: asciminib 40 mg twice daily
Number of subjects: 0
Study 37431294 — intervention group
Group type: COMPARATOR
Intervention: bosutinib
Number of subjects: 0
Study 37431294 — intervention group
Group type: EXPERIMENTAL
Intervention: asciminib
Number of subjects: 0
Study 37431406 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Health in Adolescents (AHEAD)
Number of subjects: 91
Study 37431406 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 91
Study 37431464 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway (20-week intervention)
Number of subjects: 66
Study 37431464 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 66
Study 37431558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1666
Study 37431558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1666
Study 37431663 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model intervention
Number of subjects: 1149
Study 37431663 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1149
Study 37431838 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc) patients
Number of subjects: 39
Study 37431838 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse cutaneous SSc (dcSSc) patients
Number of subjects: 39
Study 37431838 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited cutaneous SSc (lcSSc) patients
Number of subjects: 39
Study 37431838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SSc subgroups
Number of subjects: 39
Study 37431838 — intervention group
Group type: EXPERIMENTAL
Intervention: dcSSc patients
Number of subjects: 39
Study 37431838 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39
Study 37431849 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study 37431849 — intervention group
Group type: COMPARATOR
Intervention: Standard parametric network meta-analyses
Number of subjects: 0
Study 37431855 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oestrogen in conjunction with vaginal pessaries
Number of subjects: 1002
Study 37431855 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oestrogen in conjunction with surgery
Number of subjects: 1002
Study 37431855 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen therapy
Number of subjects: 1002
Study 37432025 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L
Number of subjects: 1012
Study 37432025 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 800 L
Number of subjects: 1012
Study 37432025 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L in Scale B
Number of subjects: 1012
Study 37432025 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 500 L
Number of subjects: 1012
Study 37432031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 43
Study 37432311 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for ≥2 years
Number of subjects: 4201
Study 37432311 — intervention group
Group type: COMPARATOR
Intervention: New enrollments (<2 years since ART initiation)
Number of subjects: 4201
Study 37432422 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct aortic cannulation
Number of subjects: 2478
Study 37432430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline, 3 mg, 3 times daily for 6 weeks
Number of subjects: 810
Study 37432430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline, 3 mg, 3 times daily for 12 weeks
Number of subjects: 810
Study 37432430 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 6 weeks
Number of subjects: 810
Study 37432430 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 12 weeks
Number of subjects: 810
Study 37432723 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-txt (SMS text message-delivered cognitive behavioral therapy)
Number of subjects: 103
Study 37432723 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 103
Study 37432723 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-txt
Number of subjects: 103
Study 37432724 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based emotion regulation intervention (add-on to TAU)
Number of subjects: 60
Study 37432724 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study 37432726 — intervention group
Group type: EXPERIMENTAL
Intervention: PowerED digital health intervention (reinforcement learning-based); delivered brief motivational message via interactive voice response (IVR) call, longer motivational IVR call, or live call from a counselor over 12 weeks.
Number of subjects: 228
Study 37432736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ATG
Number of subjects: 88
Study 37432736 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG plus granulocyte colony-stimulating factor (ATG/G-CSF)
Number of subjects: 88
Study 37432736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 37432960 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based integrated classifier (IC)
Number of subjects: 197
Study 37432960 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 197
Study 37433021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF alone
Number of subjects: 352
Study 37433021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens of Ad26.RSV.preF and RSV preF protein
Number of subjects: 352
Study 37433021 — intervention group
Group type: EXPERIMENTAL
Intervention: All Ad26.RSV.preF-based regimens
Number of subjects: 352
Study 37433021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based regimens
Number of subjects: 352
Study 37433021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen comprising Ad26.RSV.preF and RSV preF protein
Number of subjects: 352
Study 37433094 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (listen to music for up to 60 minutes)
Number of subjects: 750
Study 37433094 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 750
Study 37433173 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/FA 0.4 mg tablet daily (A group)
Number of subjects: 351
Study 37433173 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/FA 0.8 mg tablet daily (B group)
Number of subjects: 351
Study 37433173 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg daily (C group, control group)
Number of subjects: 351
Study 37433230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 65
Study 37433434 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based advance care planning (ACP) tool
Number of subjects: 50
Study 37433434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video intervention)
Number of subjects: 50
Study 37433436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 37433436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 103
Study 37433436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 103
Study 37433436 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF inhibition (sunitinib or sorafenib)
Number of subjects: 103
Study 37433698 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the lifestyle score (4-5 factors)
Number of subjects: 468
Study 37433698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to each additional healthy lifestyle factor
Number of subjects: 468
Study 37433718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 60
Study 37433718 — intervention group
Group type: COMPARATOR
Intervention: Non-ICI control
Number of subjects: 60
Study 37433727 — intervention group
Group type: EXPERIMENTAL
Intervention: One-off, face-to-face consultation with a practice clinician to introduce online peer support, sign patients up to an established asthma online health community (OHC), and encourage OHC engagement.
Number of subjects: 50
Study 37433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Online peer support intervention
Number of subjects: 50
Study 37433729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered at a rate of 0.1 µg/kg/hour for 48 hours during general anaesthesia induction.
Number of subjects: 292
Study 37433729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) administered at the same rate as DEX in the control group.
Number of subjects: 292
Study 37433729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 292
Study 37433729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 292
Study 37433734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of bupivacaine
Number of subjects: 0
Study 37433734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 0
Study 37433788 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 heterologous booster
Number of subjects: 0
Study 37433788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior SARS CoV-2 infection
Number of subjects: 0
Study 37434027 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR trajectory characterized by increasing eGFR over time
Number of subjects: 377
Study 37434027 — intervention group
Group type: COMPARATOR
Intervention: Annual serum creatinine, cystatin C, urine albumin, and creatinine measurements
Number of subjects: 377
Study 37434109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Intervention for Insomnia (MBSI-I)
Number of subjects: 53
Study 37434109 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Mindfulness Based Stress Intervention for Insomnia (eMBSI-I)
Number of subjects: 53
Study 37434109 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene (SH)
Number of subjects: 53
Study 37434119 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reported outcome measures (PROMs) including Health-Related Quality of Life (HRQoL), symptom monitoring (optional ecological momentary assessment of pain and fatigue), return to work and/or nutrition questionnaires.
Number of subjects: 0
Study 37434119 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reported experience measures (PREMs) regarding satisfaction with care.
Number of subjects: 0
Study 37434165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acupuncture (HA, 7 times each chemo-cycle for 3 cycles)
Number of subjects: 249
Study 37434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture (LA, 3 times each chemo-cycle for 3 cycles)
Number of subjects: 249
Study 37434165 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 249
Study 37434165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acupuncture (HA)
Number of subjects: 249
Study 37434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture (LA)
Number of subjects: 249
Study 37434244 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation leadership
Number of subjects: 494
Study 37434244 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation climate
Number of subjects: 494
Study 37434306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (ET)
Number of subjects: 6209
Study 37434306 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to a new ET
Number of subjects: 6209
Study 37434306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ET
Number of subjects: 6209
Study 37434306 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discontinuation model
Number of subjects: 6209
Study 37434306 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL (fatigue and insomnia)
Number of subjects: 6209
Study 37434378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 80 mg
Number of subjects: 353
Study 37434378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 37435073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
Number of subjects: 60
Study 37435073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37435299 — intervention group
Group type: EXPERIMENTAL
Intervention: MedSafer reports and deprescribing patient empowerment brochures
Number of subjects: 238
Study 37435299 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medication reconciliation or MedRec) without MedSafer reports
Number of subjects: 238
Study 37435500 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy plus abiraterone
Number of subjects: 0
Study 37435500 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy plus docetaxel
Number of subjects: 0
Study 37435500 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37435565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2437
Study 37435565 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 2437
Study 37435777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 52010
Study 37435777 — intervention group
Group type: COMPARATOR
Intervention: No oral anticoagulation (no OAC)
Number of subjects: 52010
Study 37435807 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (BTA) 25 units
Number of subjects: 30
Study 37435807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 37435850 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT04
Number of subjects: 581
Study 37435850 — intervention group
Group type: COMPARATOR
Intervention: RP (ustekinumab)
Number of subjects: 581
Study 37435850 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT04 and RP
Number of subjects: 581
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Dipeptidyl-peptidase-4 (DPP-4) inhibitors
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Meglitinides
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Glucagon-like peptide 1 (GLP-1) analogues
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Insulin analogues
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Ramadan-focused patient education
Number of subjects: 5359
Study 37435938 — intervention group
Group type: COMPARATOR
Intervention: Drug dosage reduction
Number of subjects: 5359
Study 37435949 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 4551
Study 37435949 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 4551
Study 37435949 — intervention group
Group type: EXPERIMENTAL
Intervention: T-MACS
Number of subjects: 4551
Study 37435949 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured integrated clinical judgement (ICJ)
Number of subjects: 4551
Study 37435949 — intervention group
Group type: COMPARATOR
Intervention: TIMI score
Number of subjects: 4551
Study 37435949 — intervention group
Group type: COMPARATOR
Intervention: EDACS
Number of subjects: 4551
Study 37436445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cor pulmonale (ACP)
Number of subjects: 281
Study 37436445 — intervention group
Group type: EXPERIMENTAL
Intervention: RV failure (RVF)
Number of subjects: 281
Study 37436445 — intervention group
Group type: EXPERIMENTAL
Intervention: RV dysfunction
Number of subjects: 281
Study 37436445 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP in last critical care echocardiography (CCE) examination
Number of subjects: 281
Study 37436477 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended depression screening program
Number of subjects: 20
Study 37436642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sedentary and stable activity phenotype (n=136, 64%)
Number of subjects: 212
Study 37436642 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable activity phenotype (n=39, 18%)
Number of subjects: 212
Study 37436642 — intervention group
Group type: EXPERIMENTAL
Intervention: High sedentary and low sleep phenotype (n=37, 17%)
Number of subjects: 212
Study 37436669 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation (TPNS)
Number of subjects: 151
Study 37436730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-contact mental health disorder diagnosis
Number of subjects: 462864
Study 37436730 — intervention group
Group type: EXPERIMENTAL
Intervention: Any mental health disorder/psychotropic prescription
Number of subjects: 462864
Study 37436730 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic difficulties associated with mental health disorder/psychotropic prescriptions
Number of subjects: 462864
Study 37436750 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 247
Study 37436750 — intervention group
Group type: COMPARATOR
Intervention: HHHFNC
Number of subjects: 247
Study 37436792 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling and HIV/STI self-testing kits
Number of subjects: 50
Study 37436794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-physical training (8 weeks, 5 days/week, 60 minutes cognitive training via BrainHQ, plus 5 days of moderate-intensity aerobic exercise and 2 days of strength training)
Number of subjects: 24
Study 37436794 — intervention group
Group type: COMPARATOR
Intervention: Physical training (8 weeks, 5 days/week, 30-50 minutes moderate-intensity aerobic exercise and 2 days of strength training)
Number of subjects: 24
Study 37436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently vaccinated patients
Number of subjects: 792
Study 37436797 — intervention group
Group type: COMPARATOR
Intervention: Patients vaccinated more than 2 years ago
Number of subjects: 792
Study 37436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipneumococcal antibody titers
Number of subjects: 792
Study 37436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up on hospitalization, pneumonia, and death
Number of subjects: 792
Study 37436871 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed surgery (after 6:00 am)
Number of subjects: 127
Study 37436871 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 127
Study 37437144 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF-MEK inhibitor combination vemurafenib-cobimetinib
Number of subjects: 16
Study 37437359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 350
Study 37437359 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula (PF)
Number of subjects: 350
Study 37437421 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsyndromal depression symptoms
Number of subjects: 355
Study 37437421 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndromal depression symptoms
Number of subjects: 355
Study 37437421 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic
Number of subjects: 355
Study 37437575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and personalized-dosage cumulative intervention combining brain-computer interface, exoskeleton, multi-channel functional electrical stimulation, and anodal transcranial direct current stimulation
Number of subjects: 0
Study 37437601 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS) alerts based on computable phenotypes (CPs) for CKD and HTN management.
Number of subjects: 9081
Study 37437608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intensity-modulated radiotherapy (RT) with pre-operative helical tomotherapy, delivering 54 Gy/30 fractions
Number of subjects: 48
Study 37437694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive medications with goal blood pressure <140/90 mm Hg)
Number of subjects: 1444
Study 37437694 — intervention group
Group type: COMPARATOR
Intervention: Control (deferred treatment until blood pressure ≥160/105 mm Hg)
Number of subjects: 1444